[HTML][HTML] PLK1, a potential target for cancer therapy
Z Liu, Q Sun, X Wang - Translational oncology, 2017 - Elsevier
Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
The same, only different–DNA damage checkpoints and their reversal throughout the cell cycle
Cell cycle checkpoints activated by DNA double-strand breaks (DSBs) are essential for the
maintenance of the genomic integrity of proliferating cells. Following DNA damage, cells …
maintenance of the genomic integrity of proliferating cells. Following DNA damage, cells …
Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy
Combination therapies consisting of multiple short therapeutic RNAs, such as small
interfering RNA (siRNA) and microRNA (miRNA), have enormous potential in cancer …
interfering RNA (siRNA) and microRNA (miRNA), have enormous potential in cancer …
Ciliary signalling in cancer
Although tumours initiate from oncogenic changes in a cancer cell, subsequent tumour
progression and therapeutic response depend on interactions between the cancer cells and …
progression and therapeutic response depend on interactions between the cancer cells and …
Plk1 overexpression induces chromosomal instability and suppresses tumor development
Abstract Polo-like kinase 1 (Plk1) is overexpressed in a wide spectrum of human tumors,
being frequently considered as an oncogene and an attractive cancer target. However, its …
being frequently considered as an oncogene and an attractive cancer target. However, its …
[HTML][HTML] Targeting polo-like kinases: a promising therapeutic approach for cancer treatment
X Liu - Translational oncology, 2015 - Elsevier
Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple
intracellular processes including DNA replication, mitosis, and stress response. Plk1, the …
intracellular processes including DNA replication, mitosis, and stress response. Plk1, the …
Targeting Plk1 sensitizes pancreatic cancer to immune checkpoint therapy
Abstract Polo-like kinase 1 (Plk1) plays an important role in cell-cycle regulation. Recent
work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic …
work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic …
[HTML][HTML] Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
MS Lee, TL Helms, N Feng, J Gay, QE Chang, F Tian… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Purpose Though the efficacy of MEK inhibitors is being investigated in KRAS-mutant
colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy did not reveal …
colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy did not reveal …
Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents
Abstract Polo-like kinase-1 (PLK-1) plays a key role in cell cycle progression during mitosis.
Overexpression/dysfunction of PLK-1 is directly associated with cancerous transformation …
Overexpression/dysfunction of PLK-1 is directly associated with cancerous transformation …
PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus–Induced Liver Carcinogenesis
Elucidating mechanisms of hepatitis B virus (HBV)–mediated hepatocarcinogenesis is
needed to gain insights into the etiology and treatment of liver cancer. Cells where HBV is …
needed to gain insights into the etiology and treatment of liver cancer. Cells where HBV is …